The global cancer vaccines market size is expected to reach market values of USD 9 billion in 2023 and USD 24.22 billion by 2033, with a compound annual growth rate (CAGR) of 12% from 2023 to 2033. Between 2018 and 2022, the cancer vaccine market grew at a 9% CAGR.
The cancer vaccine market is driven by factors such as increasing incidence of cancer, growing awareness about cancer vaccines, and government initiatives to promote cancer research and development. One of the key factors driving the growth of the cancer vaccine market is the increasing incidence of cancer worldwide. This is due to a variety of factors, such as aging populations, changing lifestyle patterns, and environmental factors. As the incidence of cancer continues to rise, there is a greater need for effective cancer treatments, including cancer vaccines.
Get a Sample Copy of the Report:
Government initiatives are also playing a significant role in driving the growth of the cancer vaccine market. Governments around the world are investing heavily in cancer research and development, which has led to increased funding for cancer vaccine development and clinical trials. For example, the US government has launched the Cancer Moonshot initiative, which aims to accelerate cancer research and improve cancer treatment and prevention.
Key Takeaways from the Cancer Vaccines Market Study
- The market for cancer vaccines expanded at a 9% CAGR from 2018 to 2022.
- The market for cancer vaccines is anticipated to expand at a 12% CAGR from 2023 to 2033.
- The market for cancer vaccines is anticipated to reach USD 24.22 billion by 2033.
- Recombinant cancer vaccines have the biggest market share, according to Future Market Insights research.
- For the market for cancer vaccines, North America is anticipated to hold a 40% market share.
- With a share of 20% throughout the projection period, it is expected that the East & South Asia market will grow considerably.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Cancer Vaccines.” says an FMI analyst
Cancer Vaccines Market Competition
Key players in the market include companies such as Advaxis Inc., Amgen Inc., Dynavax Technologies Corporation, GlaxoSmithKline plc, Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Vaccinogen, Inc., F Hoffmann-La Roche AG, and OSE Immunotherapeutics, along with healthcare providers and technology companies among other global players.
- In January 2023, the U.K. government announced a collaboration with BioNTech, a German company, to trial potential vaccines for cancer and other illnesses, while campaigners cautioned that any breakthrough must remain affordable and accessible. Personalized mRNA therapies, including cancer vaccines that aim to activate the immune system against harmful cells, will be tested on cancer patients in England at both early and late stages. The therapies target active cancer cells and work to prevent their return. BioNTech will establish new research and development centers in the U.K., including a laboratory in Cambridge and a headquarters in London, and aim to supply 10,000 therapies to patients from September 2023 until the end of the decade.
- The firm developed one of the most widely distributed COVID-19 vaccines in collaboration with U.S. pharmaceutical firm Pfizer. The collaboration will cover various cancer types and infectious diseases affecting collectively hundreds of millions of people worldwide.
More Insights Available
- FMI, in its new offering, presents an unbiased analysis of the global Cancer Vaccines market, presenting a historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
- The study reveals essential insights based on Technology, Treatment Method, Application & Region.
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
Key Segments Profiled in the Cancer Vaccines Industry Survey
Technology:
- Recombinant Cancer Vaccines
- Whole-cell Cancer Vaccines
- Viral Vector & DNA Cancer Vaccines
- Antigen/Adjuvant Cancer Vaccines
Treatment Method:
- Preventive Vaccine
- Therapeutic Vaccine
- Application:
- Prostate Cancer
- Cervical Cancer
- Other Applications
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
